

INVEST LIKE A PRO, WITH THE PROS!





Keep reading for new coverage of **Organigram** and **Aphria** from a U.S. analyst who says cannabis sticks have bottomed.

Also, the new <u>Capital Ideas Digest</u> examines a company emerging from scandal with a turnaround underway and more than 50% upside.

www.capitalideasmedia.com

Morning Need to Know Getting you ready for your investing day

November 6, 2019

Written & compiled by Mark Bunting, Publisher, Capital Ideas Media



CANADIAN ANALYSTS' CALLS

INITIATIONS

Organigram (TSX:OGI) & Aphria (TSX:APHA;NYSE;APHA).

Cantor Fitzgerald analyst Pablo Zuanic believes Canadian cannabis stocks have hit bottom and is starting coverage on a number of the larger players although OGI and APHA are the only ones he rates an "overweight".

Zuanic says:

"Valuations are at two-year lows, and we deem them attractive based on the long-term opportunity." And he adds this roundup of positive and negative catalysts:

"Positives: in Canada: recreational sales up 50% quarter-on-quarter, more store openings and the launch of derivatives, could double the recreational market to \$2.4 billion in 2020; in Western Europe, export ramp from new capacity."

"Negatives: "vape crisis" is a source of regulatory risk, but it may also further erode the illicit market; high inventories are known and will likely result in flat sequential reported sales in the calendar thirdquarter and fourth-quarter periods, but the underlying market is robust, up 19% month-onmonth in August."

**

Photon Control (TSX:PHO) gets upgraded by Paradigm Capital to "buy" with the price target moving to \$1.50 (Canadian) from \$1.10, implying 38% upside, on an expected recovery in the semiconductor industry.

Maxar Technologies (TSX:MAXR;NYSE:MAXR). TD Securities upgrades to "speculative buy" and lifts the target to \$15 (U.S.) from \$9.50.

goeasy (TSX:GSY). Desjardins Securities raises the target to \$72 (Canadian) from \$67, lowers its 2019 EPS estimate, raises the 2020 EPS estimate, and maintains "buy". **Toromont Industries (TSX:TIH)** gets its target raised to \$79 from \$71 by National Bank with the rating staying at "outperform".

Air Canada (TSX:AC) gets upgraded by J.P. Morgan to "overweight" with the target moved to \$59 from \$50.

Parkland Fuel (TSX"PKI). CIBC nudges the target to \$51 from \$49.50 and reiterates "outperformer".

Gibson Energy (TSX:GEI). GMP FirstEnergy hikes the target to \$28 from \$26.50 and maintains "buy" following earnings results.

U.S. ANALYSTS' CALLS

INITIATIONS

Lululemon (NASDAQ:LULU) gets started at Raymond James with a "strong buy" rating and a target of \$275 (U.S.).

Nike (NYSE:NKE). Raymond James also starts coverage of the shoe and apparel maker with an "outperform" and a target of \$100.

**

Lowe's (NYSE:LOW). Credit Suisse upgrades to "outperform" and hikes the target to \$129 from \$114.

The Home Depot (NYSE:HD). Credit Suisse raises the target to \$225 from \$213.

STOCKS THAT MAY MOVE

Equitable Group (TSX:EQB) The financial services company reported Q3 adjusted earnings per share of \$3.17 (Canadian), up 19% from last year, ahead of analysts estimates of \$3.13 per share. The company also raised its dividend by 25% to 35 cents per share.

Alaris Royalty (TSX:AD) reported its largest quarter for revenue in the company's history at \$30 million, an increase of 32.3% from a year ago, and EBITDA rose 29% to \$25.9 million, as EPS came in at 57 cents per share, handily beating estimates of 44 cents.

Pollard Banknote (TSX:PBL) reported record Q3 sales of \$103.2 million, beating expectations, as net income hit \$4.4 million or 17 cents per share, but lower than last year at the same time, and missing estimates of 22 cents.

Columbia Care (NEO:CCHW). The multi-state cannabis operator said Q3 revenue rose 123% to \$22.1 million (U.S.) from last year, that it took a wider net loss of nearly \$20 million, and that it's buying The Green Solution in a stock and note deal valued at \$140 million. **Barrick Gold (TSX:ABX;NYSE:GOLD)** said Q3 adjusted profit nearly tripled to \$264 million (Canadian) or 15 cents per share from \$89 million, or 8 cents per share, a year earlier, on higher gold prices and production.

The company also raised its dividend and projected production for the next five years to be flat from current levels.

HP (NYSE:HPQ). Xerox (NYSE:XRX) is considering making a cash and stock offer for the personal computer maker at a premium to the current market cap of about \$27 billion (U.S.), according to the Wall Street Journal.

CVS Health (NYSE:CVS) beat estimates with its earnings and raised its forecast as revenue jumped nearly 37% thanks to its acquisition of Aetna health insurance.

SoftBank Group (OTC:SFTBY) reported its first quarterly loss in 14 years as its Vision Fund lost \$8.9 billion on falling valuations of technology bets such as WeWork and Uber.

MARKETS

S&P/TSX and U.S. equity futures are modestly higher with U.S. indices near all-time highs and few major news catalysts at the moment.

CURRENCIES

The Canadian dollar is down slightly at \$0.7592 (U.S.).

COMMODITIES

West Texas Intermediate is down 0.4% to \$57.02 a barrel after the American Petroleum Institute reported weekly crude inventories rose 4.3 million barrels, nearly triple the estimate.

Gold is up 0.5% at \$1,490.70 an ounce.

DAILY UPDATE



<u>Click here</u> to watch the 30-second advertisement Capital Ideas Media produced for Medexus Pharmaceuticals (TSXV:MDP) that started running this week on BNN Bloomberg for the next month.


Please email questions, comments or concerns to: *customercare@capitalideasresearch.com*

Access, insight and ideas.

Mark Bunting Publisher, Capital Ideas Media

www.capitalideasmedia.com





The information and recommendations made available here ("Information") by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any

losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

Add us to your address book

update subscription preferences